Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market to Reach USD 13.2 Billion by 2035, Driven by Rising Demand for Advanced Therapies

The global Type 1 Alpha-1 Antitrypsin Deficiency Treatment Market was valued at USD 3.6 billion in 2025 and is projected to reach USD 13.2 billion by 2035, expanding at a CAGR of 12.6% during the forecast period from 2026 to 2035. The market is gaining strong momentum as greater awareness and improved genetic and blood-based testing help uncover a historically underdiagnosed rare disease associated with serious lung and liver complications. Demand is centered on augmentation therapies, bronchodilators, corticosteroids, oxygen therapy, and emerging disease-modifying approaches, while the shift toward earlier diagnosis and long-term disease management is expanding the addressable treatment population. The rapid growth trajectory also reflects increasing interest in therapies that can address the underlying genetic cause rather than simply managing respiratory symptoms.

The most eye-catching opportunity is emerging from next-generation therapies, including gene-based and RNA-targeted approaches, which could potentially transform treatment beyond conventional intravenous augmentation therapy. Pharmaceutical and biotechnology companies are advancing novel candidates aimed at correcting the underlying protein-production or accumulation mechanisms of AATD, while specialty clinics and hospitals are strengthening multidisciplinary care and infusion services. The competitive landscape includes Grifols, CSL Behring, Takeda, AstraZeneca, GSK, and other emerging biotechnology companies, with Grifols identified as a leading player in the broader AATD treatment market. Recent regulatory activity also highlights growing innovation: the European Medicines Agency granted orphan designation in December 2025 to efdoralprin alfa for treatment of alpha-1 antitrypsin deficiency, supporting further development of new therapeutic options.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/type-1-alpha-1-antitrypsin-deficiency-treatment-market?sai-v

Recent Developments
May 2026: Sanofi reported positive Phase II ElevAATe results for efdoraprin alfa, an investigational recombinant alpha-1 antitrypsin replacement therapy. The treatment achieved and maintained normalized functional AAT levels and outperformed standard plasma-derived augmentation therapy in adults with AATD-related emphysema, strengthening the pipeline for next-generation replacement therapies.

March 2026: Beam Therapeutics reported updated Phase I/II data for BEAM-302, an investigational gene-editing therapy for AATD. A 60 mg dose produced sustained AAT levels above the protective threshold and substantially reduced mutant Z-AAT, supporting advancement toward pivotal development planned for the second half of 2026.

February 2026: A comprehensive clinical review highlighted continued development of novel AATD treatments, including inhaled and recombinant AAT, next-generation augmentation approaches, neutrophil elastase inhibitors, corrector molecules, RNA-based therapies, and gene therapies targeting the underlying genetic cause of the disease.

February 2026: EMA confirmed that an orphan designation for an RNA-editing antisense oligonucleotide targeting the SERPINA1 Z mutation had been withdrawn at the sponsor's request. The development illustrates ongoing exploration of RNA-based approaches designed to address the underlying molecular defect in AATD.

January 2026: The treatment landscape continued to evolve beyond conventional augmentation therapy, with clinical development increasingly focused on correcting mutant AAT production, increasing functional circulating AAT, and preventing abnormal protein accumulation in the liver. These approaches are particularly relevant to Type 1/PI*ZZ AATD, where both pulmonary and hepatic disease can occur.

Key Players
CSL | Takeda Pharmaceutical Company Limited | Kamada Pharmaceuticals | Grifols | Vertex Pharmaceuticals Incorporated | Arrowhead Pharmaceuticals, Inc. | Dicerna Pharmaceuticals, Inc. | Inhibrx, Inc. | Wave Life Sciences Ltd. | Mereo BioPharma Group plc | Others

Key Highlights
CSL - Holds a 21.3% share, driven by its plasma-derived alpha-1 antitrypsin replacement therapies, extensive plasma collection network, manufacturing capabilities, and global rare disease portfolio.

Takeda Pharmaceutical Company Limited - Holds a 17.8% share, supported by its rare disease portfolio, plasma-derived therapies, global R&D capabilities, and focus on innovative treatments for inherited disorders.

Kamada Pharmaceuticals - Holds a 15.6% share, strengthened by its alpha-1 antitrypsin replacement therapy expertise, plasma-derived therapeutics portfolio, and dedicated focus on rare diseases.

Grifols - Holds a 13.4% share, fueled by its vertically integrated plasma-derived medicines business, extensive plasma collection infrastructure, and therapies for immunological and rare diseases.

Vertex Pharmaceuticals Incorporated - Holds a 9.8% share, driven by its advanced genetic medicine capabilities, innovative drug development platforms, and research into therapies targeting underlying genetic causes.

Arrowhead Pharmaceuticals, Inc. - Holds a 7.2% share, supported by its RNA interference (RNAi) platform, targeted genetic therapies, and development programs for rare and metabolic diseases.

Dicerna Pharmaceuticals, Inc. - Holds a 5.1% share, strengthened by its RNAi technology platform and gene-silencing expertise for developing therapies targeting genetic and liver-related disorders.

Inhibrx, Inc. - Holds a 4.0% share, fueled by its biologics discovery platform and development of targeted therapies for rare diseases and genetic disorders.

Wave Life Sciences Ltd. - Holds a 3.1% share, driven by its stereopure oligonucleotide technology, RNA-targeted therapeutics, and precision genetic medicine research.

Mereo BioPharma Group plc - Holds a 1.8% share, supported by its rare disease drug development pipeline, biologics expertise, and focus on genetically driven disorders.

Others - Hold a combined 0.9% share, comprising emerging biotechnology companies, gene therapy developers, RNA-based therapeutic firms, and specialty pharmaceutical companies advancing next-generation treatments for Type 1 Alpha-1 Antitrypsin Deficiency.

Get the Full Report Here: https://www.datamintelligence.com/buy-now-page?report=type-1-alpha-1-antitrypsin-deficiency-treatment-market?sai-v

Market Drivers
Rising prevalence of COPD, asthma, sleep apnea, and other respiratory disorders, along with increasing surgical procedures, is driving market growth.

Growing adoption of ventilators, oxygen concentrators, anesthesia machines, nebulizers, and patient-monitoring systems is accelerating demand.

Advancements in connected devices, AI-enabled monitoring, portable respiratory equipment, and digital anesthesia systems are improving patient safety and clinical efficiency.

Market Opportunities

Growing demand for home-based respiratory care, portable oxygen systems, and remote patient monitoring is creating new opportunities.

Increasing investments in smart hospitals, critical-care infrastructure, and advanced anesthesia workstations are expanding market potential.

Integration of AI, IoT, cloud connectivity, and predictive analytics is enabling smarter respiratory and anesthesia management.

Rising healthcare investments in emerging economies, particularly across Asia Pacific, are creating additional growth opportunities.

Industry Developments
AI-enabled respiratory monitoring, connected anesthesia systems, advanced ventilators, and portable respiratory devices are transforming the market.

Digital connectivity and remote monitoring are improving respiratory-care management and workflow efficiency.

Product launches, technology upgrades, strategic partnerships, and investments in respiratory-care infrastructure are strengthening competition.

Regional Insights
North America 30.0% share: Leads the market due to advanced healthcare infrastructure, high healthcare expenditure, strong adoption of respiratory technologies, and a large number of surgical procedures.

Europe: Growth is supported by established healthcare infrastructure, an aging population, increasing respiratory diseases, and rising adoption of advanced ventilatory support.

Asia Pacific: Fastest-growing region, driven by expanding healthcare infrastructure, rising respiratory disease prevalence, growing patient populations, and increasing healthcare investments.

Latin America: Growth is supported by improving healthcare access, expanding hospital infrastructure, and increasing demand for respiratory and anesthesia equipment.

Middle East & Africa: Rising healthcare modernization, hospital construction, and investments in advanced respiratory and critical-care technologies are supporting market growth.

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/type-1-alpha-1-antitrypsin-deficiency-treatment-market?sai-v

Key Segments
➥ By Treatment

Augmentation Therapy: Represents the dominant segment, driven by its established role in increasing circulating alpha-1 antitrypsin levels and reducing the risk of progressive lung damage in eligible patients.

Medication: Represents a significant segment, supported by ongoing development and adoption of pharmacological therapies targeting the underlying disease mechanisms and associated respiratory complications.

Oxygen Therapy: Represents a major segment, fueled by increasing prevalence of advanced pulmonary impairment and the need to improve oxygenation and quality of life among patients with severe respiratory disease.

Smoking Cessation Therapy: Represents a significant segment, driven by the critical importance of eliminating tobacco exposure to slow lung function decline and reduce disease progression in individuals with alpha-1 antitrypsin deficiency.

Others: Represents a growing segment, supported by expanding use of supportive respiratory therapies, pulmonary rehabilitation, nutritional management, and emerging disease-modifying approaches.

➥ By Route of Administration

Inhaled: Represents a growing segment, driven by increasing development of inhaled therapies designed to deliver treatment directly to the lungs while improving convenience and targeted drug delivery.

Intravenous: Represents the dominant segment, supported by the established administration route for augmentation therapy and the need to achieve effective systemic alpha-1 antitrypsin levels.

Others: Represents a moderate segment, driven by emerging oral, subcutaneous, and other administration approaches aimed at improving treatment convenience, adherence, and patient outcomes.

➥ By End User

Hospitals: Represents the dominant segment, driven by the availability of specialized respiratory care, diagnostic capabilities, infusion services, and multidisciplinary management for patients with alpha-1 antitrypsin deficiency.

Ambulatory Surgical Centers: Represents a growing segment, supported by increasing adoption of outpatient treatment and monitoring services for patients requiring specialized respiratory and therapeutic care.

Others: Represents a significant segment, fueled by expanding treatment across specialty respiratory clinics, homecare settings, infusion centers, and other healthcare facilities providing long-term disease management.

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.